Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenthal, S.
Right arrow Articles by Gilbert, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenthal, S.
Right arrow Articles by Gilbert, R.

Radiology, Vol 199, 451-455, Copyright © 1996 by Radiological Society of North America

ARTICLES

Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer

SA Rosenthal, DE Linstadt, MH Leibenhaut, EJ Andras, CP Brooks, DR Stickney, GC Chang, HB Wolkov and RM Gilbert
Department of Radiation Oncology, University of California, San Francisco, USA.

PURPOSE: To examine the frequency and severity of toxicity associated with flutamide inpatients treated with total androgen suppression before and during pelvic radiation therapy (RT) for prostate cancer. MATERIALS AND METHODS: Sixty-five patients with T2b-T4 prostate cancer received flutamide and goserelin acetate for 4 months, with RT beginning at the 3rd month. Treatment records including liver function test (LFT) results at baseline and during treatment were reviewed and toxicities noted. RESULTS: In 30 (46%) of 65 patients, flutamide was discontinued prematurely. Primary reasons included elevation in LFT levels (n=14); gastro-intestinal toxicity (n=9); decreased hemoglobin level (n=2); patient refusal (n=2); and arthralgia, rash, and malaise (n=1 each). Hepatotoxicity generally was manifest as asymptomatic transaminase level elevation. Grade 3-4 hepatotoxicity was noted in four of 65 patients. Mean aspartase aminotransferase increased from 23 (baseline) to 67 U/L (during flutamide treatment) (P<.02); mean alanine aminotransferase level increased from 26 (baseline) to 94 U/L (during flutamide treatment) (P<.005). CONCLUSION: Flutamide toxicity was common. LFTs should be monitored during flutamide therapy. The role of flutamide in this treatment regimen may need to be reevaluated.


This article has been cited by other articles:


Home page
 JCOHome page
E. M. Horwitz, K. Bae, G. E. Hanks, A. Porter, D. J. Grignon, H. D. Brereton, V. Venkatesan, C. A. Lawton, S. A. Rosenthal, H. M. Sandler, et al.
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
J. Clin. Oncol., May 20, 2008; 26(15): 2497 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
M. Cetin, D. Demirci, A. Unal, M. Altinbas, M. Guven, and K. Unluhizarci
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma
Human and Experimental Toxicology, March 1, 1999; 18(3): 137 - 140.
[Abstract] [PDF]

Home page
 The OncologistHome page
D. G. McLeod
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer
Oncologist, February 1, 1997; 2(1): 18 - 27.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1996 by the Radiological Society of North America.